A Study of Gene-Activated® Human Glucocerebrosidase (GA-GCB) Enzyme Replacement Therapy in Gaucher Disease

Phase 3

Completed

Brief Summary: Gaucher disease is a rare lysosomal storage disorder caused by the deficiency of the enzyme glucocerebrosidase (GCB). Due to this deficiency of functional GCB, glucocerebroside accumulates within macrophages leading to cellular engorgement, organomegaly, and organ system dysfunction. The purpose of this study is to evaluate the efficacy of every other week dosing of Gene-Activated® Human Glucocerebrosidase (GA-GCB, velaglucerase alfa) at doses of 45 and 60 U/kg in treatment-naïve patients with type 1 Gaucher disease.

Detailed Description: Type 1 Gaucher disease, the most common form, accounts for more than 90% of all cases and does not involve the Central Nervous System (CNS). Typical manifestations of type 1 Gaucher disease include hepatomegaly, splenomegaly, thrombocytopenia, bleeding tendencies, anemia, hypermetabolism, skeletal pathology, growth retardation, pulmonary disease, and decreased quality of life. Gene-Activated® human glucocerebrosidase (GA-GCB; velaglucerase alfa) is produced in a continuous human cell line using proprietary gene-activation technology and has an identical amino acid sequence to the naturally occurring human enzyme. Velaglucerase alfa contains terminal mannose residues that target the enzyme to the macrophages-the primary target cells in Gaucher disease. This study was designed to determine the efficacy, safety and pharmacokinetics of GA-GCB in men, women, and children with Type 1 Gaucher disease. Each patients duration of treatment was 12 months.

Recruitment & Eligibility

Inclusion Criteria

Patient has a documented diagnosis of type 1 Gaucher disease, as determined by deficient glucocerebrosidase (GCB) activity relative to normal as measured in leukocytes or by genotype analysis and is willing and able to provide written informed consent prior to initiating any study-related procedures
Patient is at least 2 years of age
Patient has Gaucher disease-related anemia and
Patient has at least moderate splenomegaly or
Patient has Gaucher disease-related thrombocytopenia or
Patient has a readily palpable enlarged liver
Patient has not received treatment for Gaucher disease within 30 months prior to study entry
Female patients of child-bearing potential agree to use a medically acceptable method of contraception. Male patients must agree to use a medically acceptable method of birth control.
Patient must be sufficiently cooperative to participate in the study as judged by the Investigator.

Exclusion Criteria

Includes:

Patient has type 2 or 3 Gaucher disease or is suspected of having type 3 Gaucher disease
Patient is antibody-positive to imiglucerase during screening or has experienced an anaphylactic reaction to imiglucerase
Patient has received treatment with any investigational drug or device within the 30 days prior to study entry
Patient is Human immunodeficiency virus (HIV) positive
Patient is hepatitis positive
Patient presents with iron, folic acid and/or vitamin B12 deficiency sustained anemia during screening
Patient, patient's parent(s), or patient's legal guardian(s) is/are unable to understand the nature, scope, and possible consequences of the study
Patient has a significant comorbidity(ies)that might affect study data or confound the study results
Patient is a pregnant and/or lactating female
Patient is unable to comply with the protocol or is unlikely to complete the study, as determined by the Investigator

Arm && Interventions

Group	Intervention	Description
VPRIV®-60 U/kg, IV, every other week	VPRIV ®,	VPRIV® (velaglucerase alfa, Gene Activated® human glucocerebrosidase,GA-GCB)
VPRIV®-45 U/kg, IV, every other week	VPRIV ®,	VPRIV® (velaglucerase alfa, Gene Activated® human glucocerebrosidase, GA-GCB)

Primary Outcome Measures

Name	Time	Method
Change From Baseline to 12 Months in Hemoglobin Concentration for the 60 U/kg Treatment Group.	Week 53	Efficacy endpoint

Secondary Outcome Measures

Name	Time	Method
Change From Baseline to 12 Months in Normalized Spleen Volume (Percent Body Weight) for Each Treatment Group (Measured by Magnetic Resonance Imaging (MRI))	Week 51	12 patients in the 60 U/kg group and 13 patients in the 45 U/kg group were analyzed for efficacy in the intent to treat (ITT) population. Spleen Volume has been normalized for percent of body weight for each treatment arm. Spleen size relative to body weight = (Spleen volume \[cc\]/Body weight \[kg\])\*100
Change From Baseline to 12 Months in Hemoglobin Concentration in 45 U/kg Treatment Group	Week 53
Change From Baseline to 12 Months in Platelet Counts for Each Treatment Group.	Week 53	intent to treat (ITT) Population
Percent Change From Baseline to 12 Months in Chemokine (C-C Motif) Ligand 18 (CCL18)	Week 53
Change From Baseline to 12 Months in Normalized Liver Volume (Percent Body Weight) for Each Treatment Group (Measured by Magnetic Resonance Imaging (MRI)	Week 51	Liver Volume has been normalized for percentage of body weight for each treatment arm. Liver size relative to body weight = (Liver volume \[cc\]/Body weight \[kg\])\*100
Percent Change From Baseline to 12 Months in Plasma Chitotriosidase for Each Treatment Group	Week 53	Percent Change from Baseline to Weeks 53 by Randomized velaglucerase alfa Treatment Group - Subset of intent to treat (ITT) Population who were wild type homozygous for chitotriosidase.

Locations (5): Hipolito Yrigoyen
🇦🇷
Buenos Aires, Argentina
Sociedad Espanola de Socorros Mutuos
🇵🇾
Asuncion, Paraguay
National Research Center for Haematology
🇷🇺
Moscow, Russian Federation
Shaare Zedek Medical Center
🇮🇱
Jerusalem, Israel
La Rabta Hospital
🇹🇳
Tunis, Tunisia